Tolerance of high and low amounts of PLGA microspheres loaded with mineralocorticoid receptor antagonist in retinal target site

Journal of Controlled Release

Volumn 266, Issue , 2017, Pages 187-197

  Zhao, Min ^a,b,c   Rodríguez Villagra, Esther ^d,e   Kowalczuk, Laura ^f   Le Normand, Manon ^a,b,c   Berdugo, Marianne ^a,b,c   Levy Boukris, Rinath ^a,b,c   El Zaoui, Ikram ^a,b,c   Kaufmann, Béatrice ^g   Gurny, Robert ^g   Bravo Osuna, Irene ^d,e   Molina Martínez, Irene T ^d,e   Herrero Vanrell, Rocío ^d,e   Behar Cohen, Francine ^a,b,c,f  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Immunohistochemistry; in vivo electroretinography; in vivo optical coherence tomography; Microspheres intraocular tolerance; Mineralocorticoid receptor; Poly lactic co glycolic acid (PLGA); Spironolactone

Indexed keywords

CHEMICAL ACTIVATION; DRUG PRODUCTS; MICROSPHERES; OPTICAL TOMOGRAPHY; RATS; VISION;

ELECTRORETINOGRAPHY; IMMUNOHISTOCHEMISTRY; IN-VIVO; INTRAOCULAR; MINERALOCORTICOID RECEPTORS; POLY LACTIC-CO-GLYCOLIC ACID; SPIRONOLACTONE;

OPHTHALMOLOGY;

INTERCELLULAR ADHESION MOLECULE 1; MACROPHAGE DERIVED CHEMOKINE; MICROSPHERE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; POLYGLACTIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SPIRO; SPIRONOLACTONE; CANRENOIC ACID; LACTIC ACID; MINERALOCORTICOID ANTAGONIST; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL EXPERIMENT; AQUEOUS HUMOR; ARTICLE; BLOOD RETINA BARRIER; CONTROLLED STUDY; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; ELECTRORETINOGRAM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MACROPHAGE; MACROPHAGE ACTIVATION; MICROGLIA; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; RETINA; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VISION; VITREOUS BODY; ANATOMY AND HISTOLOGY; ANIMAL; CHEMISTRY; CILIARY BODY; DRUG EFFECT; DRUG RELEASE; INTRAVITREAL DRUG ADMINISTRATION; MALE; PHYSIOLOGY; WISTAR RAT;

ANIMALS; CANRENOIC ACID; CILIARY BODY; DRUG LIBERATION; INTRAVITREAL INJECTIONS; LACTIC ACID; MACROPHAGES; MALE; MICROGLIA; MICROSPHERES; MINERALOCORTICOID RECEPTOR ANTAGONISTS; POLYGLYCOLIC ACID; RATS, WISTAR; RETINA; SPIRONOLACTONE;

EID: 85030459410     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2017.09.029     Document Type: Article

References (45)

1. Farman, N. et al., The mineralocorticoid receptor as a novel player in skin biology: beyond the renal horizon?. Exp. Dermatol. 19:2 (2010), 100–107.
2. Nguyen Dinh Cat, A., Jaisser, F., Extrarenal effects of aldosterone. Curr. Opin. Nephrol. Hypertens. 21:2 (2012), 147–156.
3. Briet, M., Schiffrin, E.L., Vascular actions of aldosterone. J. Vasc. Res. 50:2 (2013), 89–99.
4. Feldman, R.D., Gros, R., Vascular effects of aldosterone: sorting out the receptors and the ligands. Clin. Exp. Pharmacol. Physiol. 40:12 (2013), 916–921.
5. McCurley, A., Jaffe, I.Z., Mineralocorticoid receptors in vascular function and disease. Mol. Cell. Endocrinol. 350:2 (2012), 256–265.
6. Funder, J.W., Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr. Blood Press Control 6 (2013), 129–138.
7. Funder, J.W., RALES, EPHESUS and redox. J. Steroid Biochem. Mol. Biol. 93:2–5 (2005), 121–125.
8. Pitt, B. et al., Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348:14 (2003), 1309–1321.
9. Zhao, M. et al., The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Muller glial cells. FASEB J. 24:9 (2010), 3405–3415.
10. Bousquet, E. et al., The aldosterone-mineralocorticoid receptor pathway exerts anti-inflammatory effects in endotoxin-induced uveitis. PLoS One, 7(11), 2012, e49036.
11. Zhao, M. et al., Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J. Clin. Invest. 122:7 (2012), 2672–2679.
12. Mirshahi, M., Agarwal, M.K., Receptor-mediated adrenocorticoid hormone signaling in ocular tissues. Biochem. Pharmacol. 65:8 (2003), 1207–1214.
13. Wilkinson-Berka, J.L. et al., Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ. Res. 104:1 (2009), 124–133.
14. Zhao, M. et al., Differential regulations of AQP4 and Kir4.1 by triamcinolone acetonide and dexamethasone in the healthy and inflamed retina. Invest. Ophthalmol. Vis. Sci. 52:9 (2011), 6340–6347.
15. Bousquet, E. et al., Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina 33:10 (2013), 2096–2102.
16. Bousquet, E. et al., Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina 35:12 (2015), 2505–2515.
17. Daruich, A. et al., Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog. Retin. Eye Res. 48 (2015), 82–118.
18. Daruich, A. et al., Oral mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy. Transl. Vis. Sci. Technol., 5(2), 2016, 2.
19. Ghanem, C.I. et al., Induction of rat intestinal P-glycoprotein by spironolactone and its effect on absorption of orally administered digoxin. J. Pharmacol. Exp. Ther. 318:3 (2006), 1146–1152.
20. Andres-Guerrero, V. et al., Novel biodegradable polyesteramide microspheres for controlled drug delivery in ophthalmology. J. Control. Release 211 (2015), 105–117.
21. Herrero Vanrell, R., Refojo, M.F., Biodegradable microspheres for intraocular drug administration. Arch. Soc. Esp. Oftalmol. 76:4 (2001), 203–204.
22. Herrero-Vanrell, R., Refojo, M.F., Biodegradable microspheres for vitreoretinal drug delivery. Adv. Drug Deliv. Rev. 52:1 (2001), 5–16.
23. Short, B.G., Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol. Pathol. 36:1 (2008), 49–62.
24. Rong, X. et al., Safety evaluation of poly(lactic-co-glycolic acid)/poly(lactic-acid) microspheres through intravitreal injection in rabbits. Int. J. Nanomedicine 9 (2014), 3057–3068.
25. Kim, S.J., Doherty, T.J., Cherney, E.F., Intravitreal ketorolac for chronic uveitis and macular edema: a pilot study. Arch. Ophthalmol. 130:4 (2012), 456–460.
26. Maldonado, R.M. et al., Intravitreal injection of commercially available ketorolac tromethamine in eyes with diabetic macular edema refractory to laser photocoagulation. Curr. Eye Res. 36:8 (2011), 768–773.
27. Fischer, M.D. et al., Noninvasive, in vivo assessment of mouse retinal structure using optical coherence tomography. PLoS One, 4(10), 2009, e7507.
28. Latouche, C. et al., Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system. Hypertension 59:5 (2012), 966–972.
29. Tarjus, A. et al., Neutrophil gelatinase-associated lipocalin, a novel mineralocorticoid biotarget, mediates vascular profibrotic effects of mineralocorticoids. Hypertension 66:1 (2015), 158–166.
30. Jaisser, F., Farman, N., Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology. Pharmacol. Rev. 68:1 (2016), 49–75.
31. Gergely, R. et al., Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy: a comparative study of exudative and nonexudative fellow eyes. Retina 37:6 (2017), 1084–1091.
32. Pichi, F. et al., Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int. Ophthalmol., 2016, 10.1007/s10792-016-0377-2 (Epub ahead of print).
33. Singh, R.P. et al., Oral eplerenone for the management of chronic central serous chorioretinopathy. Int. J. Ophthalmol. 8:2 (2015), 310–314.
34. Herrero Vanrell, R. et al., Nano and microtechnologies for ophthalmic administration, an overview. Drug Del. Sci. Tech. 23:2 (2013), 75–102.
35. Barcia, E. et al., Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone. Exp. Eye Res. 89:2 (2009), 238–245.
36. Amrite, A.C. et al., Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest. Ophthalmol. Vis. Sci. 47:3 (2006), 1149–1160.
37. Checa-Casalengua, P. et al., Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure. J. Control. Release 156:1 (2011), 92–100.
38. Jiang, C. et al., Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol. Vis. 13 (2007), 1783–1792.
39. Andrieu-Soler, C. et al., Intravitreous injection of PLGA microspheres encapsulating GDNF promotes the survival of photoreceptors in the rd1/rd1 mouse. Mol. Vis. 11 (2005), 1002–1011.
40. Herrero-Vanrell, R. et al., The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies. Prog. Retin. Eye Res. 42 (2014), 27–43.
41. Saishin, Y. et al., Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest. Ophthalmol. Vis. Sci. 44:11 (2003), 4989–4993.
42. Yao, J. et al., Robust cell integration from co-transplantation of biodegradable MMP2-PLGA microspheres with retinal progenitor cells. Biomaterials 32:4 (2011), 1041–1050.
43. London, N.J., Chiang, A., Haller, J.A., The dexamethasone drug delivery system: indications and evidence. Adv. Ther. 28:5 (2011), 351–366.
44. Giordano, G.G. et al., Biodegradation and tissue reaction to intravitreous biodegradable poly(D,L-lactic-co-glycolic)acid microspheres. Curr. Eye Res. 14:9 (1995), 761–768.
45. Cardillo, J.A., Souza-Filho, A.A., Oliveira, A.G., Intravitreal Bioerudivel sustained-release triamcinolone microspheres system (RETAAC). Preliminary report of its potential usefulnes for the treatment of diabetic macular edema. Arch. Soc. Esp. Oftalmol. 81:12 (2006), 675–677 (679–81).